Medication Switch Guide
Switching from Semaglutide to Tirzepatide: Dose Conversion & Timeline
Switching from Semaglutide to Tirzepatide is a clinical decision that requires understanding dose equivalence, washout considerations, and what to expect in the first weeks on the new medication.
⚠️ Medical Disclaimer
This page is for educational purposes only and does not constitute medical advice. GLP-1 medications are prescription drugs. Discuss all treatment decisions with a licensed healthcare provider who knows your complete medical history. Individual results vary significantly from clinical trial averages.
🔔 Always switch under prescriber supervision
Switching GLP-1 medications should be guided by a licensed clinician. Do not self-transition. Dose equivalence tables are approximations — individual response varies.
Why Switch from Semaglutide to Tirzepatide?
Common clinical reasons for switching include:
- Efficacy: Seeking greater weight loss efficacy (22.5% vs 14.9%)
- Tolerability: Side effects on Semaglutide that may differ with Tirzepatide's distinct mechanism or formulation
- Insurance/cost: Formulary changes or coverage shifts favoring Tirzepatide
- Mechanism upgrade: Tirzepatide is a GIP/GLP-1 dual receptor agonist vs Semaglutide's GLP-1 receptor agonist
Dose Equivalence Table
There are no formally established dose equivalence conversions between most GLP-1 medications — each drug has its own dose-response curve and receptor binding profile. The general approach is to restart at the lowest titration dose of the new agent regardless of dose achieved on the prior agent.
| When on Semaglutide | Start Tirzepatide at | Rationale |
|---|---|---|
| Any dose | 2.5 mg (weekly) | Standard re-titration recommended for all switches |
| 2.4 mg (max dose) | 2.5 mg → escalate per schedule | Even patients at maximum doses re-titrate from the starting dose |
Washout Period
No washout period required for weekly-to-weekly GLP-1 transition. The last dose of the previous drug can be substituted directly with the first dose of the new drug at the starting (titration) dose.
Semaglutide has a half-life of approximately 168 hours. Tirzepatide has a half-life of approximately 120 hours. These pharmacokinetic differences influence the transition protocol but rarely require a true drug-free washout period for GLP-1 class switches.
What to Expect: First 4 Weeks on Tirzepatide
Patients switching to a new GLP-1 agent often experience a re-emergence of GI side effects (nausea, diarrhea, constipation) during the re-titration period, similar to what occurred when starting the first medication. This is normal and expected — the body is adapting to a new receptor agonist profile.
- Week 1–2: May experience mild nausea, especially if Tirzepatide has a higher receptor affinity at baseline than Semaglutide
- Week 2–4: GI symptoms typically stabilize; weight loss progress may briefly stall during re-titration
- Week 4+: Begin first dose escalation if dose is well tolerated
- Week 12–24: Expect to see meaningful efficacy data from the new agent
Monitoring After Switching
- Schedule a follow-up at 4–8 weeks post-switch to assess tolerability and early efficacy
- Monitor weight, blood glucose (if diabetic), and GI symptom pattern
- Ensure adequate hydration throughout re-titration period
- Report any unexpected or severe adverse events promptly
Drug Comparison: Semaglutide vs Tirzepatide
| Feature | Semaglutide | Tirzepatide |
|---|---|---|
| Mechanism | GLP-1 receptor agonist | GIP/GLP-1 dual receptor agonist |
| Weight Loss (%) | 14.9% | 22.5% |
| Frequency | Weekly | Weekly |
| FDA Status | Approved 2021 | Approved 2023 |
For a full comparison, see our Semaglutide vs Tirzepatide comparison page.
📅 Dose Schedule Calculator
Plan your Tirzepatide titration schedule after switching from Semaglutide.
Plan My Tirzepatide Schedule →